Reagents
Active Awarded Last action
- Contract number
- 36C24424N0558
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 4
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,418,227
Award facts
- Contract value 33% obligated
-
- $2,139,970.96 Current, with exercised options
- $4,305,202.96 Potential, with all options
- Completion date 50% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15240, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $721,744 | |
| Other Administrative Action | -$25,261 | |
| Exercise an Option | $721,744 | |
| Supplemental Agreement for work within scope | -$180,436 | |
| Supplemental Agreement for work within scope | $902,180 | |
| Original award | $0 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $4.31M firm fixed-price delivery order by Veterans Integrated Service Network 4 on May 1, 2024, for the supply of reagents. The contract is scheduled for ultimate completion on April 23, 2029, with performance taking place in Pittsburgh, Pennsylvania. This delivery order operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract vehicle and carries no set-aside designation. The award is a child contract issued against larger indefinite delivery agreements that Progenics maintains with the Department of Veterans Affairs system.
Progenics Pharmaceuticals specializes in providing diagnostic imaging agents and radiopharmaceuticals to federal healthcare providers, with its flagship product PYLARIFY (piflufolastat F-18) serving as a critical radiopharmaceutical for positron emission tomography scans used in prostate cancer detection and imaging. The company has established itself as a primary supplier across the VA system through over 150 federal contract awards, maintaining substantial blanket purchase agreements with multiple Veterans Integrated Service Networks and a major $290M Federal Supply Schedule contract with VISN 12 through March 2030. This delivery order supports the VA's oncology diagnostic imaging programs and represents one of many task orders issued to Progenics under established master contracting vehicles serving federal healthcare requirements nationwide.
Quick answers
Who was awarded contract 36C24424N0558?
36C24424N0558 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 4 (Veterans Health Administration) on May 1, 2024.
How much is contract 36C24424N0558 worth?
The government has obligated $1,418,227 on 36C24424N0558. Its current value, with exercised options, is $2,139,971. Its potential value, with all options, is $4,305,203.
Is contract 36C24424N0558 an order under another contract?
Yes. 36C24424N0558 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24424N0558 competed?
The extent of competition for 36C24424N0558 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award